AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04707989 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketone- Promoting Food Ingredient #1
Description: Novel proprietary food ingredient (#1) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
Study NCT04707989 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ketone- Promoting Food Ingredient #2
Description: Previously characterized proprietary food ingredient (#2) that contains precursors to naturally occurring energy molecules called ketone bodies. Promotes mildly elevated blood ketone concentrations. Mixed into a beverage.
Study NCT04707989 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ketone Free Placebo
Description: Beverage that is matched to ketone-promoting food ingredient #1 beverage for appearance, taste, texture and volume. Does not contain ketones or ketone precursors.
Study NCT02962271 — intervention group
Intervention type: DEVICE
Intervention: Musculoskeletal Ultrasound
Description: Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
Study NCT02173912 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CJ-30059 (Test)
Description: Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.~Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between.
Study NCT01028339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Description: 2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
Study NCT01028339 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mannitol
Description: Mannitol
Study NCT05688046 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitors plus angiogenesis inhibitors
Description: PD-(L)1-based therapy plus Bevacizumab or Anlotinib
Study NCT05688046 — intervention group
Intervention type: DRUG
Intervention: Immune checkpoint inhibitors without angiogenesis inhibitors
Description: PD-(L)1-based therapy
Study NCT04679701 — intervention group
Intervention type: DEVICE
Intervention: Amparo Confidence Socket
Description: The Amparo Confidence Socket technology takes a different approach by starting with a prefabricated socket (https://www.amparo.world/confidence-socket-en). The socket is made from a moldable thermoplastic and has the attachment point pre-assembled. This prefabricated socket is essentially an off-the-shelf product that can be heated, then molded directly to the patient's residual limb. This removes many of the intermediate steps in traditional socket fabrication. The product's molding temperature is between 60-70 ˚C but the insulation of a silicone liner between the plastic and limb ensures safe temperatures for the patient. This process is currently used in several workshops in Europe and with approximately 50 patients currently using the product. In general, it has been shown to be safe and effective in creating below-knee prosthesis.
Study NCT03495323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: LY3300054 is a monoclonal antibody that targets programmed cell death ligand 1 (
Study NCT03495323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prexasertib
Description: Prexasertib work by preventing the cancer cells from being able to repair damaged DNA (one of the building blocks of a cell) which then leads to cell death
Study NCT02116244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Civamide Nasal Spray
Study NCT02118012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorcyclizine HCl
Description: Chlorcyclizine HCl (75 mg twice daily)
Study NCT02118012 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.
Study NCT01619683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enclomiphene citrate
Description: 12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
Study NCT01619683 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 placebo capsule per day, oral
Study NCT01967212 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Game-based swallow biofeedback
Description: The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator.
Study NCT01967212 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Swallow training without biofeedback
Description: The intervention are divided into two parts：~1. Traditional swallowing training 30 min by speech therapist.~2. Mendelsohn's maneuver and effortful swallow without biofeedback 30 min.
Study NCT01455142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec/insulin aspart
Description: Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
Study NCT02986568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cancer
Description: If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles), then perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above.~If tumor size \< 5cm, perform Fusion Total mesometrial resection (TMMR)~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy.
Study NCT02986568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine cancer
Description: Perform Fusion Peritoneal mesometrial resection (PMMR).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy.~If not, no adjuvant therapy.
Study NCT02986568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical cancer, pelvic sidewall invasion
Description: Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy. Patients with primary disease will be treated with adjvuant chemotherapy. In case of recurrent disease, bevacizumab, paclitaxel, and cisplaitn will be administered regardless of the pathologic report (bevacizumab 15mg/kg on day 1, paclitaxel 135mg/m2 on day 1, and cisplatin 50mg/m2 on day 2, of each 21 day cycle).~If not, no adjuvant therapy.
Study NCT02986568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-cervical cancer, pelvic sidewall invasion
Description: Perform Fusion Laterally extended endopelvic resection (LEER).~After surgery, appropriate adjuvant chemotherapy will be administered depending on the tumor type.
Study NCT03362073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Application of ketamine using continuous intravenous infusion method during 5 days~* Ketamine 100mg/2ml + 5% Dextrose water or Normal saline 98 ml mixed fluid~* Dose schedule: 0.05mg/kg/hr -> 0.10mg/kg/hr -> ... -> 0.5mg/kg/hr (increase dose at a rate of 0.05mg/kg/hr every 8 hours)
Study NCT03486795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: M1 stimulation
Description: stimulating primary motor cortex with anodal stimulation on right primary motor cortex and cathodal stimulation on left primary motor cortex
Study NCT03486795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMC stimulation
Description: stimulating premotor cortex with anodal stimulation on right premotor cortex and cathodal stimulation on left supraorbital area
Study NCT03486795 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: sham stimulation over both primary motor cortex and premotor cortex
Study NCT01737788 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cervical occlusion
Description: Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
Study NCT01396720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluvoxamine
Description: Fluvoxamine 100mg daily, 7 days
Study NCT01396720 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopharm
Description: Citalopharm 20mg daily, 7 days
Study NCT04468204 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SinuSonic Device
Description: A medical device that utilizes sound and pressure combined with normal breathing to relieve nasal congestion.
Study NCT04468204 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham SinuSonic Device
Description: Sham positive expiratory pressure intervention using the SinuSonic Device.
Study NCT01735513 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra-aortic embolic protection management system; Embol-X
Description: The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream.
Study NCT01735513 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intra-aortic embolic protection management system; Embol-X
Description: The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream.
Study NCT04803097 — intervention group
Intervention type: DIAGNOSTIC_TEST
Description: We took slit-lamp-adapted anterior segmental photography from pediatric cataract eyes at baseline，1 week, 2 weeks, 1 month, 3 months, and 6 months postoperatively.
Study NCT02237950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days
Study NCT02237950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole oral tablets 500mg
Description: One tablet taken orally twice daily for seven consecutive days
Study NCT02237950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% SPL7013 Gel
Description: 5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
Study NCT02237950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: 5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
Study NCT03638024 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Maternal plasma cell free fetal DNA levels
Description: Measurement Maternal plasma cell free fetal DNA levels in both groups (study and control groups)
Study NCT01761318 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Preparation and labelling of Investigational Medicinal Product:~Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Study NCT01761318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Liraglutide - Placebo
Description: Preparation and labelling of Investigational Medicinal Product:~Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.~Drug accountability:~Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial.
Study NCT00677209 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Injection of autovaccine (Autovaccine Symbiopharm)
Description: increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
Study NCT02180880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin and Oxcarbazepine
Description: Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.~Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice.
Study NCT01270282 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AM-101 0.81 mg/mL
Study NCT01270282 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01119651 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Tazarotene (Patch application in Challenge Phase)
Description: There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
Study NCT01119651 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene (Patch application in Challenge Phase)
Description: There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
Study NCT01119651 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tazarotene (Patch application in Challenge Phase)
Description: There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated \& will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
Study NCT04529928 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carillon Mitral Contour System
Description: Eligible subjects will be implanted with the Carillon Device, utilizing the Carillon Mitral Contour System. The device is a permanent implant in the coronary sinus/great cardiac vein, designed to cinch the mitral annulus. The implant procedure is minimally invasive, conducted via catheter placement.
Study NCT03078205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The dual therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
Study NCT03078205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The triple therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
Study NCT02640703 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix + Prevenar 13
Description: Different time of application
Study NCT02430766 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Irreversible electroporation (IRE)
Description: Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
Study NCT02430766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NanoKnife
Study NCT04093609 — intervention group
Intervention type: GENETIC
Intervention: XIST gene deletion
Description: detection of XIST gene deletion by fluorescence in situ hybridization
Study NCT01767688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3102
Description: Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
Study NCT03211988 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Entinostat
Description: Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
Study NCT02118311 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T Regulatory cells
Description: Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
Study NCT02118311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m\^2 IV over 1 hour on days -6 through -2 from transplant
Study NCT01633203 — intervention group
Intervention type: DRUG
Intervention: epirubicin + cisplatin + capecitabine polychemotherapy
Description: EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.~CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.~CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.~Antiemetic therapy:~* Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy~* Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis~* Symptomatic antiemetic therapy with thiethylperazine will be prescribed.~Loperamide will be prescribed in case of diarrhea.
Study NCT04018560 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Al-Anon Intensive Referral (AIR)
Description: AIR is intended to facilitate Al-Anon participation.
Study NCT04563728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveillance camera(s)
Description: the mock camera intervention is for testing whether the impression of surveillance would have the effect to reduce the recidivism of elder abuse in home settings; 2) whether less costly options (mock cameras) are as effective as surveillance camera(s) in reducing the recidivism of elder abuse; 3) feasibility and acceptability of surveillance camera(s)
Study NCT00898924 — intervention group
Intervention type: GENETIC
Intervention: molecular diagnostic method
Study NCT00898924 — intervention group
Intervention type: GENETIC
Intervention: mutation analysis